These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1414816)

  • 1. Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy.
    Lundin P; Bergström K; Nyman R; Lundberg PO; Muhr C
    AJNR Am J Neuroradiol; 1992; 13(5):1279-91. PubMed ID: 1414816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chiasmal herniation as a complication of bromocriptine therapy.
    Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
    J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
    Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
    Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
    Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
    Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR volumetry for monitoring intramuscular bromocriptine treatment in macroprolactinomas.
    Benesch H; Felber SR; Finkenstedt G; Kremser C; Stockhammer G; Aichner FT
    J Comput Assist Tomogr; 1995; 19(6):866-70. PubMed ID: 8537517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
    van 't Verlaat JW; Croughs RJ
    Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
    Tyson D; Reggiardo D; Sklar C; David R
    Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.
    Orrego JJ; Chandler WF; Barkan AL
    Pituitary; 2000 Nov; 3(3):189-92. PubMed ID: 11383485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macroprolactinomas with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies.
    Ahmed M; al-Dossary E; Woodhouse NJ
    Fertil Steril; 1992 Sep; 58(3):492-7. PubMed ID: 1521641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.
    Araújo C; Marques O; Almeida R; Santos MJ
    Endocrine; 2018 Nov; 62(2):470-476. PubMed ID: 30088141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
    van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ
    Can J Neurol Sci; 1990 Feb; 17(1):71-3. PubMed ID: 2311021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bromocriptine for macroprolactinomas. Discussion of 3 cases treated successfully].
    Sapunar J; López JM; Huete I; Tagle R
    Rev Med Chil; 1992 Feb; 120(2):168-73. PubMed ID: 1340555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
    Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.